Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
NCT02461589 on ClinicalTrials.gov · last registry update 2019-07-31
An unusually large phase 2: 706 participants, more than double the 110 typical for the stage. The sponsor logged completion for 13 October 2016. Primary outcome, as filed: Change in HbA1c (Glycosylated Haemoglobin). semaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 706
- Started
- 2015-09-21
- Primary completion
- 2016-10-13 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in HbA1c (Glycosylated Haemoglobin)
Conditions studied
Diabetes · Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.